title: Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
abstract: Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.
authors.affiliation: Department of Internal Medicine, Division of Cardiology.
authors.forename: Elizabeth Ashley
authors.initials: EA
authors.lastname: Hardin
authors.affiliation: Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Kelly M
authors.initials: KM
authors.lastname: Chin
mesh_terms: D000081:Acetamides / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D065627:Familial Primary Pulmonary Hypertension; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D011719:Pyrazines / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D013618:Tachyphylaxis
chemical_list: D000081:Acetamides; D000959:Antihypertensive Agents; D011719:Pyrazines; C523468:selexipag; D011464:Epoprostenol
keywords: prostacyclin; pulmonary arterial hypertension; selexipag